12-Month Intraocular Pressure and Hypotensive Medications Outcomes After Phaco-ELIOS Procedure-A Real World Study
Abstract
PRÉCIS: Combined phaco-ELIOS in ocular hypertension and glaucoma showed a statistically significant reduction in the number of hypotensive medications of 1.5 compared with baseline, with 78.4% of eyes being medication-free at 12 months.
PURPOSE: To describe the change in medication and intraocular pressure 12 months after the combined phacoemulsification-ELIOS procedure.
METHODS: Retrospective, multicenter interventional case series of adults with ocular hypertension or glaucoma undergoing phaco-ELIOS. Clinical data were collected and analyzed from preoperative baseline up to 12 months postoperatively. The primary outcome was the mean change in medication compared with baseline. Secondary outcomes were intraocular pressure change from baseline, incidence of acute postoperative intraocular pressure elevation, and surgical success at 1 year, defined as intraocular pressure reduction of ≥20% compared with baseline with no increase in medications, or reduction of ≥1 medications compared with baseline with intraocular pressure equal or below baseline, with no secondary glaucoma surgeries and no loss of light perception.
RESULTS: One hundred twelve eyes were included. Forty-two patients (51.2%) were female. Mean (±SD) age was 70.6 (±9.6) years. The most frequent diagnosis was primary open angle glaucoma (71.4%). The mean number of medications at baseline and 12 months was 1.8 (±0.8) and 0.4 (±0.7), respectively, representing a reduction of 1.5 (±1.0) ( P <0.0001). At the end of…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- eggNOG 5.0: a hierarchical, functionally and phylogenetically annotated orthology resource based on 5090 organisms and 2502 viruses
- Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
- OptiType: precision HLA typing from next-generation sequencing data
- Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications
- Saccharomyces cerevisiae cells have three Omega class glutathione S-transferases acting as 1-Cys thiol transferases
- Hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.